Loading clinical trials...

Non-interventional Observational Study of Helical Tomotherapy for Oligometastatic Colorectal Cancer | Clinical Trials | Clareo Health

COMPLETED

Non-interventional Observational Study of Helical Tomotherapy for Oligometastatic Colorectal Cancer

NCT00807313•Universitair Ziekenhuis Brussel

View on ClinicalTrials.gov

Summary

Patients with oligometastatic colorectal cancer (5 metastases or less) receive a combination of systemic treatment and often local treatment, such as surgery, radiofrequency ablation and more recently stereotactic body radiotherapy. The aim of this study is to register the results and side effects of stereotactic body radiotherapy (SBRT) by means of helical tomotherapy in the treatment of oligometastatic colorectal cancer. The trial has two cohorts. Patients in cohort I get consolidation SBRT after best response on first line chemotherapy. Patients in cohort II get SBRT when there is progression under, or no indication for (further) chemotherapy. The primary endpoint is to evaluate the metabolic complete remission rate three months after the start of radiotherapy.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with (residual) oligometastatic CRC: ≤ 5 mets
•Primary tumor treated with curative intention (surgery, radiotherapy, chemoradiotherapy)
•Functional liver volume \> 1000cc if livermets, lung DLCO \> 30% if lungmets.
•No Child B or C liver cirrhosis
•No contra-indications for radiation of all metastatic CRC (= no violation of constraints of organs at risk (OAR))
•No mets from another carcinoma
•Age \> 18 years
•WHO-PS ≤ 2

Locations (1)

UZ Brussel, Vrije Universiteit Brussel, dienst Radiotherapie

Brussels, Belgium

Key Dates

Start Date

December 1, 2008

Primary Completion Date

July 1, 2011

Completion Date

November 30, 2020

Last Updated

December 29, 2020

Enrollment

ACTUAL participants

Conditions

Colon CancerRectal CancerColorectal Cancer

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

NCT06696768

Metastatic Colorectal AdenocarcinomaStage III Colorectal Cancer AJCC v8+2 more

View study

RECRUITINGPHASE1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 29, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Non-interventional Observational Study of Helical Tomotherapy for Oligometastatic Colorectal Cancer

Inclusion Criteria

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Resilience and Equity in Aging, Cancer, and Health (REACH)